ClinicalTrials.gg
Active, not recruitingNCT07246941POINT-HDUpdated Sep 2, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

A Phase 1 interventional study of RG6496 and Placebo in Huntington's Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 7 sites in 5 countries. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Huntington Disease with a site in Australia — 5 open to participants now, 9 under way, 3 of them phase 3. Huntington Disease · Australia.

Enrollment
24th of 24
3 · median 149
Started
2025
with 1 other
Phase 1
2 of 28
1 open now
Registered
25th of 28
by date
Lead sponsor
3 of 28
Hoffmann-La Roche

Among the 28 studies in Huntington Disease with a site in Australia, this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 25th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

5 of the 28 studies in Huntington Disease with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Huntington Disease with a site in Australia, or all of them as a file.
02

Study summary

This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs). The study consists of two parts: Part 1 [single-ascending dose] followed by Part 2 [open-label extension (OLE)].

03

Conditions studied

  • Huntington's Disease

Browse trials for

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1

  • Confirmation of HDGEC status with cytosine-adenine-guanine (CAG) expansion > 39.
  • Confirmation of SNP carrier status of the target SNP
  • Independence Scale (IS) score of ≥70, total functional capacity (TFC) ≥10, total motor score (TMS) >6.
  • Ability to read the words "red," "blue," and "green" and be fluent in the language of the form (ICF) and the tests used at the study site.
  • Ability to walk unassisted.
  • Total body weight > 40 kilogram (kg) and (BMI) within the range 18-32 kilogram per square meter (kg/m\^2) (inclusive) at baseline.
  • Ability to undergo and tolerate MRI scans.

Part 2

  • Completed the post-dose safety follow-up period in the Part 1 of the study.
  • In the opinion of the Investigator, the participant has not experienced a worsening in health that precludes their safe continued participation in the study.

Exclusion criteria

Exclusion Criteria:

Part 1

  • Concurrent or planned participation in any interventional clinical study, including current use of an ASO or any HTT-lowering therapy or treatment with therapy within 90 days or 5 drug-elimination half-lives, whichever is longer prior to screening
  • Pregnant or breastfeeding, or with the intention of becoming pregnant during the study or within the timeframe in which is required
  • within 5 years prior to screening
  • Planned brain surgery during the study
  • Positive test, surface antigen and hepatitis B surface antigen at screening
  • Active psychosis, confusional state, or violent behavior, including aggression that could cause harm to self or others, over the 12 weeks prior to screening.
  • Current or previous history of a primary independent psychotic disorder.
  • Scoliosis or spinal deformity or surgery making IT injection not feasible in an outpatient setting
  • History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that required hospital visit and/or change in level of care within 12 months prior to screening.

Part 2

  • Prematurely discontinued from Part 1 for any reason (i.e., before the completion of the postdose safety follow-up period of Part 1).
  • Pregnant or breastfeeding, or with the intention of becoming pregnant during the study or within the timeframe in which contraception is required.
  • Concurrent or planned participation in any interventional clinical study, including current use of an ASO or any HTT-lowering therapy
  • Received any active investigational treatment other than RG6496 during or since completion of Part 1 of the study.
  • Had confirmed Dose-Limiting Adverse Event (DLAE)(s) in Part 1 of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Part 1: RG6496

    Participants will receive single dose of RG6496. Participants will be enrolled in planned sequential cohorts associated with ascending dose levels.

    Drug: RG6496

  • Placebo comparator
    Part 1: Placebo

    Participants will receive a single dose of RG6496 matching placebo.

    Drug: Placebo

  • Experimental
    Part 2: OLE

    All participants who have completed Part 1 and are eligible for Part 2 will receive one open-label dose of RG6496.

    Drug: RG6496

Interventions

  • DrugRG6496

    RG6496 will be administered as per the schedule specified in the respective arms.

  • DrugPlacebo

    RG6496 matching placebo will be administered as per the schedule specified in placebo arm.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 24 months

  2. Part 1: Change From Baseline in Neurological Assessment

    A neurologic examination including fundoscopy, will be performed by a neurologist or an ophthalmologist depending on local practice. A neurologic examination will include an assessment of mental status, level of consciousness, cranial nerve function, motor function, sensory function, reflexes, gait, and coordination.

    Time frame: Up to approximately 24 months

  3. Part 1: Percentage of Participants With Suicidal Ideation or Behavior, as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    C-SSRS measures 4 constructs as follows: severity of ideation, intensity of ideation, behavior, and lethality of actual suicide attempts. Binary (yes/no) data are collected for 10 categories. Numeric ratings are provided for intensity of ideation (if present), from 1 to 5, with 1 being the least severe and 5 being the most severe.

    Time frame: Up to approximately 24 months

  4. Part 1: Change from Baseline in Montreal Cognitive Assessment (MoCA)

    MoCA is a rater-administered, participant completed assessment (PerfO instrument) used to detect cognitive impairment. It contains a series of basic assessments, including attention and visuospatial tasks. The total score ranges from 0 to 30, where lower scores indicate greater impairment.

    Time frame: Up to approximately 24 months

  5. Part 2: Number of Participants With AEs

    Time frame: Up to approximately 38 months

  6. Part 2: Change From Baseline in Neurological Assessment

    A neurologic examination including fundoscopy, will be performed by a neurologist or an ophthalmologist depending on local practice. A neurologic examination will include an assessment of mental status, level of consciousness, cranial nerve function, motor function, sensory function, reflexes, gait, and coordination.

    Time frame: Up to approximately 38 months

  7. Part 2: Number of Participants With Suicidal Ideation or Behavior, as Assessed by C-SSRS Score

    C-SSRS measures 4 constructs as follows: severity of ideation, intensity of ideation, behavior, and lethality of actual suicide attempts. Binary (yes/no) data are collected for 10 categories. Numeric ratings are provided for intensity of ideation (if present), from 1 to 5, with 1 being the least severe and 5 being the most severe.

    Time frame: Up to approximately 38 months

  8. Part 2: Change from Baseline in MoCA

    MoCA is a rater-administered, participant completed assessment (PerfO instrument) used to detect cognitive impairment. It contains a series of basic assessments, including attention and visuospatial tasks. The total score ranges from 0 to 30, where lower scores indicate greater impairment.

    Time frame: Up to approximately 38 months

Secondary outcomes

  1. Part 1: Plasma Concentration of RG6496

    Time frame: Up to approximately 24 months

  2. Part 1 and Part 2: Number of Participants With Anti-drug Antibody (ADA) in Plasma to RG6496

    Time frame: Part 1: Up to approximately 24 months; Part 2: Up to approximately 38 months

  3. Part 1 and Part 2: Change From Baseline of Mutant Huntingtin Protein (mHTT) Concentrations in Cerebrospinal Fluid (CSF) Over Time

    Time frame: Part 1: Up to approximately 24 months; Part 2: Up to approximately 38 months

07

Study locations

7 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 19 phase 1 interventional studies under Huntington Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 24, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07246941
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Nov 19, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion